99mTc-HPArk2 SPECT/CT in the evaluation of HER2-positive breast cancer: a pilot prospective study
Conclusions: This pilot study indicated that the uptake of HER2 antagonist 99mTc-HPArk2 correlate with HER2 expression in breast cancer. 99mTc-HPArk2 SPECT/CT can provide specific, non-invasive evaluation of HER2 expression in breast cancer.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Wang, R., Zhou, Y., Du, S., Shi, J., Zhu, Z., Wang, F. Tags: Breast Cancer I Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | HER2 | Mammography | Nuclear Medicine | PET Scan | SPECT | Study